<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38433036</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Human immunology</Title><ISOAbbreviation>Hum Immunol</ISOAbbreviation></Journal><ArticleTitle>Investigating viral and autoimmune T cell responses associated with post-acute sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>110770</StartPage><MedlinePgn>110770</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humimm.2024.110770</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0198-8859(24)00026-0</ELocationID><Abstract><AbstractText>Post-acute sequelae of COVID-19 (PASC), or Long COVID, is a chronic condition following acute SARS-CoV-2 infection. Symptoms include exertion fatigue, respiratory issues, myalgia, and neurological manifestations such as 'brain fog,' posing concern for their debilitating nature and potential role in other neurological disorders. However, the underlying potential pathogenic mechanisms of the neurological complications of PASC is largely unknown. Herein, we investigated differences in antigen-specific T cell responses from the peripheral blood towards SARS-CoV-2, latent viruses, or neuronal antigens in 14 PASC individuals with neurological manifestations (PASC-N) versus 22 individuals fully recovered from COVID-19. We employed Activation Induced Marker (AIM), ICS and FluoroSpot assays to determine the specificity and magnitude of CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses towards SARS-CoV-2 (Spike and rest of proteome), latent viruses (CMV, EBV), and several neuronal antigens. Overall, we observed similar antigen-specific T cell frequencies and cytokine effector T cell responses between PASC donors compared to recovered controls for all antigens tested (viral or autoantigen) in both CD4<sup>+</sup> and CD8<sup>+</sup> T cell compartments. Our findings suggest that PASC-N does not appear to be associated with changes in antigen-specific T cell responses towards a subset of disease-relevant targets, but more studies in a larger cohort are needed to confirm these unaltered responses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Gregory P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Esther Dawen</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Kendra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freuchet</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frazier</LastName><ForeName>April</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindestam Arlehamn</LastName><ForeName>Cecilia S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sette</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA; University of California San Diego School of Medicine, La Jolla, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva Antunes</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, San Diego, CA, USA. Electronic address: rantunes@lji.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI118626</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI142742</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Immunol</MedlineTA><NlmUniqueID>8010936</NlmUniqueID><ISSNLinking>0198-8859</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="Y">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="Y">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Neuroantigens</Keyword><Keyword MajorTopicYN="N">Neuroimmunology</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post Acute Sequelae SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cell</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>4</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>3</Day><Hour>21</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38433036</ArticleId><ArticleId IdType="mid">NIHMS1974185</ArticleId><ArticleId IdType="pmc">PMC11144566</ArticleId><ArticleId IdType="doi">10.1016/j.humimm.2024.110770</ArticleId><ArticleId IdType="pii">S0198-8859(24)00026-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z, Xie Y &amp; Bowe B High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259&#x2013;264, doi:10.1038/s41586-021-03553-9 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M &amp; Goodman SN Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open 4, e2111417, doi:10.1001/jamanetworkopen.2021.11417 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine 55, 101762, doi:10.1016/j.eclinm.2022.101762 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla AK et al. An observational multi-centric COVID-19 sequelae study among health care workers. Lancet Reg Health Southeast Asia 10, 100129, doi:10.1016/j.lansea.2022.100129 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2022.100129</ArticleId><ArticleId IdType="pmc">PMC9744681</ArticleId><ArticleId IdType="pubmed">36531928</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomogida K et al. Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged &gt;/=18 Years - Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep 70, 1274&#x2013;1277, doi:10.15585/mmwr.mm7037a2 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7037a2</ArticleId><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM &amp; Topol EJ Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133&#x2013;146, doi:10.1038/s41579-022-00846-2 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S &amp; Merad M Pathological sequelae of long-haul COVID. Nat Immunol 23, 194&#x2013;202, doi:10.1038/s41590-021-01104-y (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M &amp; Iwasaki A The neurobiology of long COVID. Neuron 110, 3484&#x2013;3496, doi:10.1016/j.neuron.2022.10.006 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghimi N et al. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep 21, 44, doi:10.1007/s11910-021-01130-1 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-021-01130-1</ArticleId><ArticleId IdType="pmc">PMC8237541</ArticleId><ArticleId IdType="pubmed">34181102</ArticleId></ArticleIdList></Reference><Reference><Citation>Teodoro T, Chen J, Gelauff J &amp; Edwards MJ Functional neurological disorder in people with long COVID: A systematic review. Eur J Neurol, doi:10.1111/ene.15721 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15721</ArticleId><ArticleId IdType="pubmed">36719069</ArticleId></ArticleIdList></Reference><Reference><Citation>Caress JB et al. COVID-19-associated Guillain-Barre syndrome: The early pandemic experience. Muscle Nerve 62, 485&#x2013;491, doi:10.1002/mus.27024 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27024</ArticleId><ArticleId IdType="pmc">PMC7405390</ArticleId><ArticleId IdType="pubmed">32678460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L et al. Association of COVID-19 with New-Onset Alzheimer&#x2019;s Disease. J Alzheimers Dis 89, 411&#x2013;414, doi:10.3233/JAD-220717 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-220717</ArticleId><ArticleId IdType="pmc">PMC10361652</ArticleId><ArticleId IdType="pubmed">35912749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali SS et al. New-onset Parkinsonism as a Covid-19 infection sequela: A systematic review and meta-analysis. Ann Med Surg (Lond) 80, 104281, doi:10.1016/j.amsu.2022.104281 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.104281</ArticleId><ArticleId IdType="pmc">PMC9359766</ArticleId><ArticleId IdType="pubmed">35971509</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881&#x2013;895 e820, doi:10.1016/j.cell.2022.01.014 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM &amp; Haagmans BL SARS-CoV-2 pathogenesis. Nat Rev Microbiol 20, 270&#x2013;284, doi:10.1038/s41579-022-00713-0 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J &amp; Laurence J Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest 132, doi:10.1172/JCI161167 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758&#x2013;763, doi:10.1038/s41586-022-05542-y (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol, doi:10.1038/s41590-023-01601-2 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield KM et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog 18, e1010359, doi:10.1371/journal.ppat.1010359 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId><ArticleId IdType="pmc">PMC9176759</ArticleId><ArticleId IdType="pubmed">35617421</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho CY et al. Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19. JAMA Neurol 79, 544&#x2013;553, doi:10.1001/jamaneurol.2022.0154 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.0154</ArticleId><ArticleId IdType="pmc">PMC9002725</ArticleId><ArticleId IdType="pubmed">35404378</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE &amp; Hurley DJ Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens 10, doi:10.3390/pathogens10060763 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Impact of Pre-Existing Chronic Viral Infection and Reactivation on the Development of Long COVID. medRxiv, doi:10.1101/2022.06.21.22276660 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, doi:10.1126/science.abd4585 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY et al. Diverse Functional Autoantibodies in Patients with COVID-19. medRxiv, doi:10.1101/2020.12.10.20247205 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.10.20247205</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 4, 100100, doi:10.1016/j.jtauto.2021.100100 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Sidney J &amp; Crotty S T Cell Responses to SARS-CoV-2. Annu Rev Immunol, doi:10.1146/annurev-immunol-101721-061120 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-101721-061120</ArticleId><ArticleId IdType="pubmed">36750314</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Antunes R et al. The MegaPool Approach to Characterize Adaptive CD4+ and CD8+ T Cell Responses. Curr Protoc 3, e934, doi:10.1002/cpz1.934 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpz1.934</ArticleId><ArticleId IdType="pmc">PMC10662678</ArticleId><ArticleId IdType="pubmed">37966108</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489&#x2013;1501 e1415, doi:10.1016/j.cell.2020.05.015 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu ED et al. Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status. Cell Host Microbe 30, 388&#x2013;399 e383, doi:10.1016/j.chom.2022.02.003 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC8824221</ArticleId><ArticleId IdType="pubmed">35172129</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco Pro S et al. Automatic Generation of Validated Specific Epitope Sets. J Immunol Res 2015, 763461, doi:10.1155/2015/763461 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/763461</ArticleId><ArticleId IdType="pmc">PMC4629045</ArticleId><ArticleId IdType="pubmed">26568965</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM et al. A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. J Immunol 197, 983&#x2013;993, doi:10.4049/jimmunol.1600318 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1600318</ArticleId><ArticleId IdType="pmc">PMC4955771</ArticleId><ArticleId IdType="pubmed">27342848</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Antunes R et al. Development and Validation of a Bordetella pertussis WholeGenome Screening Strategy. J Immunol Res 2020, 8202067, doi:10.1155/2020/8202067 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8202067</ArticleId><ArticleId IdType="pmc">PMC7154976</ArticleId><ArticleId IdType="pubmed">32322598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847&#x2013;859 e811, doi:10.1016/j.cell.2022.01.015 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu ED et al. Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. Cell Host Microbe 30, 1269&#x2013;1278 e1264, doi:10.1016/j.chom.2022.07.012 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.07.012</ArticleId><ArticleId IdType="pmc">PMC9296686</ArticleId><ArticleId IdType="pubmed">35932763</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanwani R et al. Transcriptional analysis of peripheral memory T cells reveals Parkinson&#x2019;s disease-specific gene signatures. NPJ Parkinsons Dis 8, 30, doi:10.1038/s41531-022-00282-2 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-022-00282-2</ArticleId><ArticleId IdType="pmc">PMC8938520</ArticleId><ArticleId IdType="pubmed">35314697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindestam Arlehamn CS et al. alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson&#x2019;s disease. Nat Commun 11, 1875, doi:10.1038/s41467-020-15626-w (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15626-w</ArticleId><ArticleId IdType="pmc">PMC7171193</ArticleId><ArticleId IdType="pubmed">32313102</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Castaneda A et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 185, 2452&#x2013;2468 e2416, doi:10.1016/j.cell.2022.06.008 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J et al. Distinguishing features of long COVID identified through immune profiling. Nature 623, 139&#x2013;148, doi:10.1038/s41586-023-06651-y (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuerten S et al. Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. Proc Natl Acad Sci U S A 117, 21512&#x2013;21518, doi:10.1073/pnas.2011249117 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2011249117</ArticleId><ArticleId IdType="pmc">PMC7474673</ArticleId><ArticleId IdType="pubmed">32817492</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin R, McFarland HF &amp; McFarlin DE Immunological aspects of demyelinating diseases. Annu Rev Immunol 10, 153&#x2013;187, doi:10.1146/annurev.iy.10.040192.001101 (1992).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.10.040192.001101</ArticleId><ArticleId IdType="pubmed">1375472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota K et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346, 183&#x2013;187, doi:10.1038/346183a0 (1990).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/346183a0</ArticleId><ArticleId IdType="pubmed">1694970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D et al. T cells from patients with Parkinson&#x2019;s disease recognize alpha-synuclein peptides. Nature 546, 656&#x2013;661, doi:10.1038/nature22815 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22815</ArticleId><ArticleId IdType="pmc">PMC5626019</ArticleId><ArticleId IdType="pubmed">28636593</ArticleId></ArticleIdList></Reference><Reference><Citation>Opsteen S, Files JK, Fram T &amp; Erdmann N The role of immune activation and antigen persistence in acute and long COVID. J Investig Med, 10815589231158041, doi:10.1177/10815589231158041 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10815589231158041</ArticleId><ArticleId IdType="pmc">PMC9996119</ArticleId><ArticleId IdType="pubmed">36879504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif ZA et al. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 12, doi:10.7554/eLife.86002 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A &amp; Crotty S Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev 310, 27&#x2013;46, doi:10.1111/imr.13089 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13089</ArticleId><ArticleId IdType="pmc">PMC9349657</ArticleId><ArticleId IdType="pubmed">35733376</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM et al. Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity. Nat Commun 14, 5139, doi:10.1038/s41467-023-40460-1 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40460-1</ArticleId><ArticleId IdType="pmc">PMC10447583</ArticleId><ArticleId IdType="pubmed">37612310</ArticleId></ArticleIdList></Reference><Reference><Citation>Galan M et al. Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers. Front Immunol 13, 848886, doi:10.3389/fimmu.2022.848886 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.848886</ArticleId><ArticleId IdType="pmc">PMC8990790</ArticleId><ArticleId IdType="pubmed">35401523</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 36, 109518, doi:10.1016/j.celrep.2021.109518 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M &amp; Iwasaki A Unexplained post-acute infection syndromes. Nat Med 28, 911&#x2013;923, doi:10.1038/s41591-022-01810-6 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Boufidou F et al. SARS-CoV-2 Reinfections and Long COVID in the Post-Omicron Phase of the Pandemic. Int J Mol Sci 24, doi:10.3390/ijms241612962 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241612962</ArticleId><ArticleId IdType="pmc">PMC10454552</ArticleId><ArticleId IdType="pubmed">37629143</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L et al. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein. Front Immunol 14, 1155770, doi:10.3389/fimmu.2023.1155770 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1155770</ArticleId><ArticleId IdType="pmc">PMC10258318</ArticleId><ArticleId IdType="pubmed">37313412</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL et al. Persistent neurologic symptoms and cognitive dysfunction in nonhospitalized Covid-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol 8, 1073&#x2013;1085, doi:10.1002/acn3.51350 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer JM et al. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120 ( Pt 8), 1447&#x2013;1460, doi:10.1093/brain/120.8.1447 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.8.1447</ArticleId><ArticleId IdType="pubmed">9278634</ArticleId></ArticleIdList></Reference><Reference><Citation>Pender MP et al. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 165, 5322&#x2013;5331, doi:10.4049/jimmunol.165.9.5322 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.9.5322</ArticleId><ArticleId IdType="pubmed">11046067</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto DG et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature 620, 128&#x2013;136, doi:10.1038/s41586-023-06331-x (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06331-x</ArticleId><ArticleId IdType="pmc">PMC10396966</ArticleId><ArticleId IdType="pubmed">37468623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>